Abstract:Abstract Idiopathic pulmonary fibrosis (IPF) is a severe disorder leading to progressive and irreversible loss of pulmonary function. In this study we investigated the anti-fibrotic effect of vitamin D using a mouse model of IPF. Lung fibrosis was induced with bleomycin in vitamin D-sufficient and vitamin D-deficient C57BL/6 mice. We found that treatment with active vitamin D analog paricalcitol prevented mouse body weight loss and alleviated lung fibrosis, whereas vitamin D deficiency severely aggravated lung injury. At the molecular level, paricalcitol treatment suppressed the induction of fibrotic inducer TGF-β and extracellular matrix proteins α-SMA, collagen type I and fibronectin in the lung, whereas vitamin D deficiency exacerbated the induction of these proteins. Interestingly, bleomycin treatment activated the local renin–angiotensin system (RAS) in the lung, manifested by the induction of renin, angiotensinogen, angiotensin II and angiotensin receptor type 1 (AT1R). Paricalcitol treatment suppressed the induction of these RAS components, whereas vitamin D deficiency enhanced the activation of the lung RAS. We also showed that treatment of bleomycin-induced vitamin D-deficient mice with AT1R antagonist losartan relieved weight loss, substantially ameliorated lung fibrosis and markedly blocked TGF-β induction in the lung. Moreover, we demonstrated that in lung fibroblast cultures, TGF-β and angiotensin II synergistically induced TGF-β, AT1R, α-SMA, collagen type I and fibronectin, whereas 1,25-dihydroxyvitamin D markedly suppressed the induction of these fibrotic markers. Collectively, these observations strongly suggest that vitamin D mitigates lung fibrosis by blocking the activation of the lung RAS in this mouse model of IPF.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the pathogenesis of idiopathic pulmonary fibrosis (IPF) and its potential treatment strategies. Specifically, the researchers explored the role of vitamin D in inhibiting bleomycin (BLM) - induced pulmonary fibrosis in mice and whether it exerts an anti - fibrosis effect by targeting the local renin - angiotensin system (RAS) in the lungs. The research background indicates that IPF is a serious disease that leads to progressive and irreversible loss of lung function. The bleomycin - induced mouse pulmonary fibrosis model is often used in IPF research. The vitamin D endocrine system plays multiple roles in human and animal physiology and pathophysiology, including regulating calcium homeostasis and bone health, as well as the recently reported regulation of cell proliferation, antioxidant and anti - inflammatory effects. Importantly, the vitamin D hormone is a negative endocrine regulator of the renin - angiotensin system. The renin - angiotensin system plays a crucial role in regulating blood pressure, salt and fluid balance, but the local renin - angiotensin system in different tissues has various biological activities. Angiotensin II is the central effector molecule of the renin - angiotensin system and has strong pro - inflammatory and pro - fibrotic activities. Based on these backgrounds, the researchers hypothesized that vitamin D may reduce bleomycin - induced lung injury by blocking the activation of the local renin - angiotensin system in the lungs. The paper provides evidence to support this hypothesis by using the vitamin D analogue paricalcitol for treatment and a vitamin D - deficient model. The research results show that paricalcitol can prevent the weight loss of mice induced by bleomycin and significantly relieve pulmonary fibrosis; while vitamin D deficiency exacerbates lung injury. In addition, treatment with losartan, an AT1 receptor antagonist that blocks the renin - angiotensin system, can also significantly improve the pulmonary fibrosis in vitamin D - deficient mice. These findings emphasize the important role of vitamin D in protecting the lungs from fibrotic damage.

Vitamin D suppresses bleomycin-induced pulmonary fibrosis by targeting the local renin–angiotensin system in the lung

Astragaloside Iv Improves Bleomycin-Induced Pulmonary Fibrosis in Rats by Attenuating Extracellular Matrix Deposition

Vitamin D3 alleviates pulmonary fibrosis by regulating the MAPK pathway via targeting PSAT1 expression in vivo and in vitro

Atorvastatin attenuates bleomycin-induced pulmonary fibrosis via suppressing iNOS expression and the CTGF (CCN2)/ERK signaling pathway.

IFN-γ-Inducible Protein-10 Attenuates Bleomycin-Induced Pulmonary Fibrosis Via Inhibition of Angiogenesis

Fibroblast Upregulation of Vitamin D Receptor Represents a Self-Protective Response to Limit Fibroblast Proliferation and Activation during Pulmonary Fibrosis

Anti-Fibrotic Effects of Low Toxic Microcystin-RR on Bleomycin-Induced Pulmonary Fibrosis: A Comparison with Microcystin-LR

Antifibrotic effects of vitamin D3 on human lung fibroblasts derived from patients with idiopathic pulmonary fibrosis

Dopamine Receptor Agonists Ameliorate Bleomycin-Induced Pulmonary Fibrosis by Repressing Fibroblast Differentiation and Proliferation.

Alpinetin ameliorates bleomycin-induced pulmonary fibrosis by repressing fibroblast differentiation and proliferation

Inhibition of ferroptosis and iron accumulation alleviates pulmonary fibrosis in a bleomycin model

Evogliptin Attenuates Bleomycin-Induced Lung Fibrosis Via Inhibiting TGF-β/Smad Signaling in Fibroblast

Tenofovir Alafenamide Fumarate Attenuates Bleomycin-Induced Pulmonary Fibrosis by Upregulating the NS5ATP9 and TGF-β1/Smad3 Signaling Pathway.

Interleukin-38 overexpression prevents bleomycin-induced mouse pulmonary fibrosis

Overexpression of fatty acid synthase attenuates bleomycin induced lung fibrosis by restoring mitochondrial dysfunction in mice

Danshensu alleviates bleomycin-induced pulmonary fibrosis by inhibiting lung fibroblast-to-myofibroblast transition via the MEK/ERK signaling pathway

Imatinib Mesylate Inhibits Bleomycin-Induced Pulmonary Fibrosis in Mice: the Mechanism

Asarinin attenuates bleomycin-induced pulmonary fibrosis by activating PPARγ

Sunitinib, a Small-Molecule Kinase Inhibitor, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice.

Therapeutic Effects of the Bcl-2 Inhibitor on Bleomycin-induced Pulmonary Fibrosis in Mice

Angiotensin-Converting Enzyme 2 Attenuates Bleomycin-Induced Lung Fibrosis in Mice